Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This is an open-label, non-randomized, phase 2 study to assess the feasibility of using cabozantinib in recurrent/metastatic Merkel Cell Carcinoma patients that progressed after platinum-based therapy.
Epistemonikos ID: 18c33502dd78e5430de90a81e04f6e7f9fd1b075
First added on: May 11, 2024